Fotemustine
Muphoran · Nitrosourea (alkylating)
Class delayed cumulative tubulointerstitial/ATN; usually mild; acute signal often really cisplatin.
Nidran · ACNU
Nitrosourea (alkylating) · approved 1979 · 4 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A water-soluble nitrosourea workhorse for gliomas — its renal risk is inferred from the class (cumulative tubulointerstitial injury) because drug-specific human renal data are genuinely thin.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Drug-specific human renal-toxicity data for nimustine are thin; renal risk is asserted largely at the class level. Like other nitrosoureas, cumulative dosing is associated with delayed tubulointerstitial injury and CKD, but a reliable nimustine-specific incidence is not established. Dose-limiting toxicity is hematologic (delayed myelosuppression).Source: Kessler et al., Rev Med Interne 1991 (class-level)
Delayed and cumulative — typically over months of repeated cycles, like the nitrosourea class.
Distilled from: “Delayed and cumulative — typically over months of repeated cycles, mirroring the nitrosourea class.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Slow, cumulative tubulointerstitial scarring — fibrosis, tubular atrophy and glomerulosclerosis with no discrete acute phase. The nitrosourea (carmustine/lomustine) lesion and delayed radioligand (radiation) nephropathy; often irreversible and detected only as a creeping creatinine months to years later.
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Tap a signature to trace where it strikes the nephron.
Chronic Interstitial Nephropathy strikes: Interstitium.
Chronic Interstitial Nephropathy
Slow, cumulative tubulointerstitial scarring — fibrosis, tubular atrophy and glomerulosclerosis with no discrete acute phase. The nitrosourea (carmustine/lomustine) lesion and delayed radioligand (radiation) nephropathy; often irreversible and detected only as a creeping creatinine months to years later.
Nimustine (ACNU) is a water-soluble chloroethyl-nitrosourea alkylating agent. It alkylates DNA (chloroethylation at O6-guanine) to form interstrand cross-links, causing cell-cycle-independent cytotoxicity; its water solubility and CNS penetration make it a mainstay (especially historically and in Asia/Europe) for malignant gliomas, often combined with radiotherapy.
Class-level context for the major non-renal toxicities of the Nitrosourea (alkylating) class.
Ophthalmic
Keratopathy, uveitis, retinopathy
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
4 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Everything below is FAERS — adverse events someone chose to report, about 60 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Counted by the report's active-substance field, which FAERS fills almost only on reports received from 2013 on, so these figures describe reports since then, not the agent's whole history.
Reported with a death outcome
17 of 60 reports
Reported with hospitalization
8 of 60 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 2 of the 60 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Nimustine (ACNU) sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Muphoran · Nitrosourea (alkylating)
Class delayed cumulative tubulointerstitial/ATN; usually mild; acute signal often really cisplatin.
Alimta · Antifolate
Cumulative chronic tubulointerstitial injury; RTA and nephrogenic DI.
Zelboraf · BRAF inhibitor
Strongest renal offender of the BRAF/MEK class: proximal tubular injury/Fanconi and early AKI.
Pluvicto · Radioligand therapy (PSMA)
PSMA-targeted radioligand for prostate cancer; renal radiation exposure and xerostomia.
Pepaxto · Peptide-conjugated alkylator
Delivers melphalan intracellularly; BRIDGE supports a reduced 30 mg dose in moderate renal impairment.
Yondelis · Marine alkylating agent
Rhabdomyolysis → pigment nephropathy; hepatotoxicity.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.